MAPT and Alzheimer disease: As one of the most probable hypotheses, that accumulation of advanced glycation end products (Vistoli et al., 2013), a biomarker implicated in the development and progression of oxidative-based diseases such as DM (Yamagishi et al., 2012) and AD (Sasaki et al., 1998; Grillo and Colombatto, 2008; Li et al., 2012), may play a role in neurodegeneration given the co-localization of advanced glycation end products in the Aβ and tau pathology in AD (Sasaki et al., 1998; Grillo and Colombatto, 2008; Li et al., 2012).